Is there discrimination in access to therapy for HCV patients?
Garattini
Silvio
S
D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D002170:Canada; D018153:Czech Republic; D005062:European Union; D006297:Health Services Accessibility; D054625:Healthcare Disparities / Q000191:economics*; D016174:Hepacivirus; D006526:Hepatitis C / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000191:economics / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000191:economics / Q000627:therapeutic use; D011287:Prejudice; D011994:Recombinant Proteins; D012254:Ribavirin / Q000191:economics / Q000627:therapeutic use
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a